Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx
Immunovia

Advancing early detection of pancreatic cancer

Immunovia’s vision is to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.

About us

About Immunovia

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.

Read more about Immunovia

Decorative image
May 2024

Redeye Investor Forum

Listen to Immunovia CEO Jeff Borcherding’s presentation from Redeye Investor Forum.

See the presentation